Skip to Content

Zarxio Approval History

Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.

Development History and FDA Approval Process for Zarxio

Mar  6, 2015Approval FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)
Jan  7, 2015Sandoz Biosimilar Filgrastim Recommended for Approval

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.